Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent bendamustine as lymphodepleti...
Saved in:
| Main Authors: | Crystal Mackall, Holden T Maecker, Lekha Mikkilineni, Melody Smith, Saurabh Dahiya, Bita Sahaf, David Miklos, Sally Arai, Surbhi Sidana, Wen-Kai Weng, Dasom Lee, Anmol Goyal, Sushma Bharadwaj, Eric Lau, Mark P Hamilton, Hrishi Srinagesh, Alexandria Jensen, Jayasindhu Mallampet, Sarah Elkordy, Shriya Syal, Sunita Patil, Theresa Latchford, Laura J Johnston, Robert Lowsky, Robert Negrin, Andrew R Rezvani, Judith Shizuru, Everett H Meyer, Parveen Shiraz, Lori Muffly, Matthew J Frank |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/7/e008975.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
by: Frederick L. Locke, et al.
Published: (2025-06-01) -
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
by: Xuefeng Wang, et al.
Published: (2025-07-01) -
Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
by: Yuan Tian, et al.
Published: (2025-02-01) -
Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy
by: Yao Qi, et al.
Published: (2025-06-01) -
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
by: Andrew J. Portuguese, et al.
Published: (2025-03-01)